Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Abdominal Cancer Clear all
Completed Phase 1 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

NCT00005830
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
Interventions
Doxorubicin Hydrochloride, Cisplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Phase 2 Interventional Results available

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

NCT01534637
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
aprepitant, gemcitabine hydrochloride, capecitabine, fluorouracil, radiation therapy, questionnaire administration, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications
Drug · Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Jul 22, 2026, 10:18 AM EDT
Terminated Phase 2 Interventional

Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy

NCT00505492
View directory record Official record
Conditions
Uterine Neoplasms
Interventions
Carboplatin, Cisplatin, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2011 · Synced Jul 22, 2026, 10:18 AM EDT
Recruiting Phase 2 Interventional

Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)

NCT07282834
View directory record Official record
Conditions
Peritoneal (Metastatic) Cancer, Peritoneal Carcinomatosis, Abdominal Cancer, Abdominal Cancer Patients
Interventions
Heated intra-peritoneal chemotherapy, Aerosolized intra-peritoneal chemotherapy
Procedure
Lead sponsor
Patrick Wagner, MD, FACS
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Phase 2 Interventional Results available

Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)

NCT01902953
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Lymphoseek and VBD Sln dissection
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jul 22, 2026, 10:18 AM EDT
Recruiting Early Phase 1 Interventional

PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis

NCT06511037
View directory record Official record
Conditions
Gastrointestinal Cancer, Peritoneal Carcinomatosis
Interventions
Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 22, 2026, 10:18 AM EDT
Completed No phase listed Observational

Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers

NCT00086567
View directory record Official record
Conditions
Fallopian Tube Cancer, Peritoneal Neoplasms, Epithelial Ovarian Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Evanston, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Phase 1 Interventional

Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI

NCT02833753
View directory record Official record
Conditions
Colorectal Cancer, Appendix Cancer, Peritoneal Carcinomatosis
Interventions
Oxaliplatin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Jul 22, 2026, 10:18 AM EDT
Terminated Not applicable Interventional

Precision Pain Management for Major Abdominal Surgery in Colorectal Surgery

NCT03455751
View directory record Official record
Conditions
Colorectal Cancer, Diverticular Disease, Crohn Disease, Ulcerative Colitis
Interventions
PGx-guided post-operative pain management
Genetic
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Jul 22, 2026, 10:18 AM EDT
Not listed Phase 2 Interventional

Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis

NCT03073694
View directory record Official record
Conditions
Cancer, Appendiceal, ColoRectal Cancer
Interventions
Mitomycin c, Melphalan
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Jul 22, 2026, 10:18 AM EDT
Completed No phase listed Observational

Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes

NCT04988490
View directory record Official record
Conditions
Post-Surgical Pain, Post-Surgical Complication, Cancer, Cannabis Use
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 22, 2026, 10:18 AM EDT
Withdrawn Phase 1 Interventional

Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity

NCT00942838
View directory record Official record
Conditions
Recurrent Ovarian Carcinoma
Interventions
Cisplatin, Whole Abdomen Radiotherapy
Drug · Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Phase 2 Interventional

Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer

NCT00063401
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions
Cetuximab:, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2010 · Synced Jul 22, 2026, 10:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626
View directory record Official record
Conditions
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm
Interventions
STAR0602
Drug
Lead sponsor
Marengo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Loma Linda, California • Sacramento, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Phase 3 Interventional

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus

NCT00002546
View directory record Official record
Conditions
Sarcoma
Interventions
cisplatin, ifosfamide, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
21 Years to 120 Years · Female only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Gatos, California + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Not applicable Interventional

Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer

NCT01764789
View directory record Official record
Conditions
Anxiety Disorder, Depression, Fatigue, Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pain, Peritoneal Carcinomatosis, Pseudomyxoma Peritonei, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Gestational Trophoblastic Tumor, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
Interventions
questionnaire administration, quality-of-life assessment, psychosocial assessment and care, behavioral intervention, cognitive intervention, educational intervention
Other · Procedure · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years to 85 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Jul 22, 2026, 10:18 AM EDT
Not yet recruiting Phase 1 Interventional

TLR9 Immunotherapy for Peritoneal Carcinomatosis

NCT07658196
View directory record Official record
Conditions
Malignant Ascites, Colorectal Adenocarcinoma, Peritoneal (Metastatic) Cancer, Appendiceal Adenocarcinoma
Interventions
ACM-CpG
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Phase 1 Interventional

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

NCT00436657
View directory record Official record
Conditions
Peritoneal Neoplasms, Retroperitoneal Neoplasms, Gastrointestinal Neoplasms, Adenocarcinoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Adrenocortical Carcinoma, Wilms Tumor, Rhabdomyosarcoma, Desmoplastic Small Round Cell Tumor
Interventions
CHPP of Cisplatin, Abdominal Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2012 · Synced Jul 22, 2026, 10:18 AM EDT
Active, not recruiting Not applicable Interventional

Structured Post-Operative Pain and Distress Treatment Intervention for Patients Undergoing Surgery for Intra-Abdominal Malignancies

NCT06858202
View directory record Official record
Conditions
Psychological Distress, Intra-abdominal Cancer
Interventions
Mindfulness Intervention, Non-mindfulness Intervention
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Not applicable Interventional

High-dose Periop Statins for Prevention of DVT

NCT00259662
View directory record Official record
Conditions
Gynecologic Oncological Pelvic/Abdominal Surgery
Interventions
atorvastatin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Jul 22, 2026, 10:18 AM EDT
Completed No phase listed Observational

Respiratory Tumor and Normal Tissue Motion

NCT00415675
View directory record Official record
Conditions
Lung Cancer, Abdominal Cancer
Interventions
Motion CT Scans
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

NSS-2 BRIDGE Device in Post-Operative Pain Management

NCT03555266
View directory record Official record
Conditions
Acute Pain, Surgery, Abdominal Cancer
Interventions
NSS-2 Bridge, Sham NSS-2 BRIDGE
Device
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 10:18 AM EDT
Completed Phase 2 Interventional

EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer

NCT00035100
View directory record Official record
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions
epothilone b
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 15, 2012 · Synced Jul 22, 2026, 10:18 AM EDT
Terminated Not applicable Interventional

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

NCT00087191
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
EF5, motexafin lutetium, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Jul 22, 2026, 10:18 AM EDT